-
Zeitschrift Fur Hautkrankheiten 1975A randomized double-blind left-right comparative trial was carried out between a new steroid Desoximetason 0,25% (Ibaril) and fluocinolone acetonide 0,025% cream.... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
A randomized double-blind left-right comparative trial was carried out between a new steroid Desoximetason 0,25% (Ibaril) and fluocinolone acetonide 0,025% cream. Evaluation of symptoms on 50 patients suffering from endogenous eczema was recorded after 1, 2, 3 and 4 weeks. There was a significantly better effect of Ibaril compared to Fluocinolone-acetonide as judged by the observer during the 1st, 3rd and 4th week of treatment. After the 2nd week treatment Ibaril showed a better effect, however, a significancy could not be established.
Topics: Clinical Trials as Topic; Dermatitis, Contact; Dermatitis, Seborrheic; Dexamethasone; Drug Evaluation; Eczema; Fluocinolone Acetonide; Humans
PubMed: 132779
DOI: No ID Found -
Gastroenterology Nursing : the Official... 2014
Topics: Desoximetasone; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin Antagonists; Vomiting
PubMed: 24691090
DOI: 10.1097/SGA.0000000000000040 -
Dermatologic Therapy Jul 2019Topical potent corticosteroids are the mainstay of treatment for chronic hand eczema (CHE). However, there are numerous adverse effects associated with the chronic use... (Comparative Study)
Comparative Study Randomized Controlled Trial
Topical potent corticosteroids are the mainstay of treatment for chronic hand eczema (CHE). However, there are numerous adverse effects associated with the chronic use of topical corticosteroids. Calcipotriol has been widely used in psoriasis and has been reported to achieve beneficial effects in several inflammatory diseases. This study aimed to evaluate the efficacy and safety of calcipotriol ointment compared to desoximetasone ointment in the treatment of CHE. Patch testing was performed in all recruited subjects. Then, each hand of the patient was randomly allocated for the application of either calcipotriol ointment or desoximetasone ointment twice daily for 8 weeks. Recurrence was assessed 4 weeks after discontinuation of the treatment. The Hand eczema severity index (HECSI) scores, quartile grading assessments and digital photographs were evaluated. Adverse reactions were also monitored. A total of 13 participants completed the protocol. Mean HECSI scores revealed up to a 75% reduction in both treatments (p < .001) without significant differences between the groups (p > .05). Approximately 70% of the subjects reported more than 75% improvement with calcipotriol at the end of the treatment. Mild scaling and mild dryness were the most common reactions found with calcipotriol and desoximetasone, respectively. In conclusion, calcipotriol ointment is safe and as effective as desoximetasone ointment. Calcipotriol ointment may be an alternative treatment option for CHE.
Topics: Administration, Cutaneous; Adult; Aged; Calcitriol; Chronic Disease; Dermatologic Agents; Desoximetasone; Double-Blind Method; Eczema; Female; Glucocorticoids; Hand Dermatoses; Humans; Male; Middle Aged; Ointments; Prospective Studies; Treatment Outcome
PubMed: 31070845
DOI: 10.1111/dth.12956 -
Journal of Cutaneous Medicine and... 2009Tacrolimus is often coadministered with various topical corticosteroids in the treatment of steroid-responsive dermatoses; however, the stability of these products in... (Comparative Study)
Comparative Study
BACKGROUND
Tacrolimus is often coadministered with various topical corticosteroids in the treatment of steroid-responsive dermatoses; however, the stability of these products in combination has not been examined extensively.
OBJECTIVE
To assess the in vitro compatibility of three tacrolimus-corticosteroid ointment combinations compared with unmixed controls.
METHODS
Tacrolimus-clobetasol propionate, tacrolimus-desoximetasone, and tacrolimus-hydrocortisone-17-valerate ointment combinations were prepared, stored with unmixed ointments at three temperature/humidity conditions, and evaluated for stability at days 0, 1, 2, 7, 14, and 28 via reverse-phase high-performance liquid chromatography.
RESULTS
There was no significant difference in the rate of drug degradation in mixed and unmixed ointments over time or across temperatures for tacrolimus (time p = .94; temperature p = .44), clobetasol (time p = .98, temperature p = .30), desoximetasone (time p = .98; temperature p = .94), or hydrocortisone-17-valerate (time p = .87, temperature p = .36).
LIMITATIONS
This study did not examine the compatibility of tacrolimus with nonointment formulations.
CONCLUSION
Tacrolimus-clobetasol propionate (superpotent), tacrolimus-desoximetasone (high potent), and tacrolimus-hydrocortisone-17-valerate (midpotent) ointment combinations are chemically compatible for at least 4 weeks.
Topics: Administration, Cutaneous; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Drug Interactions; Drug Stability; Drug Therapy, Combination; Glucocorticoids; Humans; Immunosuppressive Agents; Ointments; Skin Diseases; Tacrolimus
PubMed: 19426622
DOI: 10.2310/7750.2008.08013 -
Recent Patents on Nanotechnology Jan 2013The applications of Pulsed Laser Deposition (PLD) for producing nanoparticles, nanostructures and nanocomposites coatings based on recently developed laser ablating... (Review)
Review
The applications of Pulsed Laser Deposition (PLD) for producing nanoparticles, nanostructures and nanocomposites coatings based on recently developed laser ablating techniques and their convergence are being reviewed. The problems of in situ synthesis of hybrid inorganic-organic nanocomposites coatings by these techniques are being discussed. The novel modification of PLD called Pulsed Laser Adaptive Deposition (PLAD) technique is presented. The in situ synthesized inorganic/organic nanocomposites coatings from Magnesium (Mg) alloy/Rhodamine B and Mg alloy/ Desoximetasone by PLAD are described. The trends, applications and future development of discussed patented methods based on the laser ablating technologies for producing hybrid nanocomposite coatings have also been discussed in this review.
Topics: Alloys; Desoximetasone; Lasers; Magnesium; Metals; Nanocomposites; Patents as Topic; Rhodamines
PubMed: 22747717
DOI: No ID Found -
The American Journal of Medicine Sep 2020
Topics: Adult; Anti-Inflammatory Agents; Desoximetasone; Female; Humans; Hydroxyzine; Mastocytosis
PubMed: 32004505
DOI: 10.1016/j.amjmed.2019.12.036 -
Proceedings (Baylor University. Medical... Jul 2018We report the first case of a 34-year-old woman with histiocytoid Sweet syndrome (HSS) that was successfully treated with etanercept. HSS is a rare histological variant...
We report the first case of a 34-year-old woman with histiocytoid Sweet syndrome (HSS) that was successfully treated with etanercept. HSS is a rare histological variant of acute febrile neutrophilic dermatosis that was described by Requena et al in 2005. It is distinguished by dermal infiltration by mononuclear cells with a histiocytic morphology. To date there are three reported cases of the use of etanercept in the treatment of classic febrile neutrophilic dermatosis but none targeting this disease variant. Our patient presented with a 6-month history of scattered erythematous papules on the neck, trunk, and upper and lower limbs bilaterally. Clinical findings and histopathological evaluation were highly suggestive of HSS. After 32 months of refractory disease activity, our patient was initiated on a regimen of etanercept 1 mg/kg subcutaneously twice weekly and topical desoximetasone 0.05% ointment twice daily as required. To date, our patient has achieved 37 months of remission.
PubMed: 29904308
DOI: 10.1080/08998280.2018.1460132 -
The Journal of Dermatological Treatment Feb 2021: To determine if resistance to topical treatments can be overcome under conditions promoting adherence.: Twelve psoriasis patients treated with topical 0.25%... (Clinical Trial)
Clinical Trial
: To determine if resistance to topical treatments can be overcome under conditions promoting adherence.: Twelve psoriasis patients treated with topical 0.25% desoximetasone spray were randomized to either twice daily phone call reminders or no phone call and were treated for 2 weeks. Pruritus Visual Analog Scale (VAS), Psoriasis Area and Severity Index (PASI), Total Lesion Severity Score (TLSS), and, Investigator Global Assessment (IGA) assessed disease severity.: Most subjects improved in most scoring parameters. 100%, 91.7%, 83.3%, and 58.3% had improvements in itching, PASI, TLSS, and IGA, respectively.: While our sample size was small and treatment duration short, the effect size of topical treatment was large under conditions designed to promote adherence.
Topics: Administration, Topical; Adult; Aged; Desoximetasone; Drug Administration Schedule; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome
PubMed: 31132897
DOI: 10.1080/09546634.2019.1617830 -
Clinical Therapeutics 1986A double-blind, multicenter study was conducted to evaluate and compare the safety and efficacy of desoximetasone gel 0.05% and fluocinonide gel 0.05% in patients with... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
A double-blind, multicenter study was conducted to evaluate and compare the safety and efficacy of desoximetasone gel 0.05% and fluocinonide gel 0.05% in patients with scalp psoriasis. One hundred twenty-five patients were enrolled in this randomized, parallel-group trial. Responses based on clinical assessment in 123 patients showed that the desoximetasone gel formulation is a safe and effective treatment for psoriasis of the scalp. Although efficacy appears equivalent to that of fluocinonide gel 0.05% in treating psoriasis of the scalp, desoximetasone appears to be slightly better tolerated and better accepted cosmetically.
Topics: Administration, Topical; Adolescent; Adult; Aged; Clinical Trials as Topic; Desoximetasone; Dexamethasone; Double-Blind Method; Female; Fluocinolone Acetonide; Fluocinonide; Gels; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses
PubMed: 3521856
DOI: No ID Found -
Cutis Feb 2020Most patients with psoriasis have limited disease that should be manageable with topical treatment. However, psoriasis often is resistant to topical treatment. The aim... (Randomized Controlled Trial)
Randomized Controlled Trial
Most patients with psoriasis have limited disease that should be manageable with topical treatment. However, psoriasis often is resistant to topical treatment. The aim of our study was to determine if patients using psoriasis-resistant topical treatments can be effectively treated with topicals under conditions promoting adherence. During this open-label, randomized, single-center clinical study, 12 patients with moderate psoriasis that previously failed topical treatment were selected and treated with desoximetasone spray 0.25% for 2 weeks. Six patients were randomized to receive twice-daily telephone call reminders to further encourage good adherence. Disease severity was assessed by the visual analog scale for pruritus, psoriasis area and severity index (PASI), total lesion severity score (TLSS), and investigator global assessment (IGA). At the end of the study, most patients improved in most scores. Therefore, apparent resistance to topical treatment often is due to poor adherence and can be overcome, at least over the short term.
Topics: Administration, Cutaneous; Aged; Anti-Inflammatory Agents; Desoximetasone; Female; Humans; Male; Medication Adherence; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome; Visual Analog Scale
PubMed: 32186523
DOI: No ID Found